"
CPT codes, descriptions and other data only are copyright 2019 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

List Revisions: 1) Code 0091U was deleted (This code is not covered by CMS National Coverage Determination (NCD) for Colorectal Cancer Screening Tests (210.3)). 2) Code 0081U shares the same code descriptor as code 8XX03. 3) 0080U was approved as an Advanced Diagnostic Laboratory Test (ADLT) and was deleted.  4)Code 0104U was deleted (effective, 10/1/2019).  5.) Code 8XX0X is a new code; column C was revised. 6) Codes 81406, 81350, 81484 and 81407  are not substantially revised codes and were deleted. 7) Codes 0111U and 0112U are new Proprietary Laboratory Analyses (PLA) codes"			
Item #	Code #	Code Type	Long Code Descriptor
1	81163	Reconsider-Molecular Pathology	Gene analysis (breast cancer 1 and 2) of full sequence
2	81165	Reconsider-Molecular Pathology	Gene analysis (breast cancer 1) of full sequence
3	0046U	Reconsider--Proprietary Laboratory Analyses	Gene analysis (fms-related tyrosine kinase 3) for internal tandem duplication variants
4	0049U	Reconsider--Proprietary Laboratory Analyses	Gene analysis (nucleophosmin)
5	813X1	New--Molecular Pathology	"PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence"
6	813X2	New--Molecular Pathology	"PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; known familial variant"
7	8XX01	New--Molecular Pathology	"PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, and 20)"
8	0062U	New--Proprietary Laboratory Analyses	"Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score"
9	0063U	New--Proprietary Laboratory Analyses	"Neurology (autism), 32 amines by LC-MS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder"
10	0064U	New--Proprietary Laboratory Analyses	"Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative"
11	0065U	New--Proprietary Laboratory Analyses	"Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)"
12	0066U	New--Proprietary Laboratory Analyses	"Placental alpha-micro globulin-1 (PAMG-1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen"
13	0067U	New--Proprietary Laboratory Analyses	"Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score"
14	0068U	New--Proprietary Laboratory Analyses	"Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C. tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species"
15	0069U	New--Proprietary Laboratory Analyses	"Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score"
16	0070U	New--Proprietary Laboratory Analyses	"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xN)"
17	0071U	New--Proprietary Laboratory Analyses	"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence "
18	0072U	New--Proprietary Laboratory Analyses	"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene)"
19	0073U	New--Proprietary Laboratory Analyses	"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene)"
20	0074U	New--Proprietary Laboratory Analyses	"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans)"
21	0075U	New--Proprietary Laboratory Analyses	"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5 gene duplication/multiplication)"
22	0076U	New--Proprietary Laboratory Analyses	"CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3 gene duplication/ multiplication)"
23	0077U	New--Proprietary Laboratory Analyses	"Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype"
24	0078U	New--Proprietary Laboratory Analyses	"Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder"
25	0080U	New--Proprietary Laboratory Analyses	"Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy"
25	"0081U/
8XX03"	New--Proprietary Laboratory Analyses	"Oncology (uveal melanoma), mRNA, gene-expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping genes), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis"
26	0082U	New--Proprietary Laboratory Analyses	"Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service"
27	0083U	New--Proprietary Laboratory Analyses	"Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations"
28	0084U	New--Proprietary Laboratory Analyses	"Red blood cell antigen typing, DNA, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens"
29	0085U	New--Proprietary Laboratory Analyses	"Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA)"
30	0086U	New--Proprietary Laboratory Analyses	"Infectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility"
31	0087U	New--Proprietary Laboratory Analyses	"Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score"
32	0088U	New--Proprietary Laboratory Analyses	"Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection"
33	0089U	New--Proprietary Laboratory Analyses	"Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es)"
34	0090U	New--Proprietary Laboratory Analyses	"Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a categorical result (ie, benign, indeterminate, malignant)"
36	0091U	New--Proprietary Laboratory Analyses	"Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result

Note: This code is not covered by CMS National Coverage Determination (NCD) for Colorectal Cancer Screening Tests (210.3). For additional information, please see: https://www.cms.gov/medicare-coverage-database/(S(v0cxhe45alguxjupvjx24zai))/details/ncd-details.aspx?NCDId=281&ncdver=5&CALId=97&ver=5&CalName=Prothrombin%2BTime%2Band%2BFecal%2BOccult%2BBlood%2B(Revision%2Bof%2BICD-9-CM%2BCodes%2Bfor%2BInjury%2Bto%2BGastrointestinal%2BTract)&bc=gAgAAAAAgAIAAA%3D%3D"
35	0092U	New--Proprietary Laboratory Analyses	"Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy"
36	0093U	New--Proprietary Laboratory Analyses	"Prescription drug monitoring, evaluation of 65 common drugs by LC-MS/MS, urine, each drug reported detected or not detected"
37	0094U	New--Proprietary Laboratory Analyses	"Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis"
38	0095U	New--Proprietary Laboratory Analyses	"Inflammation (eosinophilic esophagitis), ELISA analysis of eotaxin-3 (CCL26 [C-C motif chemokine ligand 26]) and major basic protein (PRG2 [proteoglycan 2, pro eosinophil major basic protein]), specimen obtained by swallowed nylon string, algorithm reported as predictive probability index for active eosinophilic esophagitis"
39	0096U	New--Proprietary Laboratory Analyses	"Human papillomavirus (HPV), high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), male urine"
40	0097U	New--Proprietary Laboratory Analyses	"Gastrointestinal pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 22 targets (Campylobacter [C. jejuni/C. coli/C. upsaliensis], Clostridium difficile [C. difficile] toxin A/B, Plesiomonas shigelloides, Salmonella, Vibrio [V. parahaemolyticus/V. vulnificus/V. cholerae], including specific identification of Vibrio cholerae, Yersinia enterocolitica, Enteroaggregative Escherichia coli [EAEC], Enteropathogenic Escherichia coli [EPEC], Enterotoxigenic Escherichia coli [ETEC] lt/st, Shiga-like toxin-producing Escherichia coli [STEC] stx1/stx2 [including specific identification of the E. coli O157 serogroup within STEC], Shigella/Enteroinvasive Escherichia coli [EIEC], Cryptosporidium, Cyclospora cayetanensis, Entamoeba histolytica, Giardia lamblia [also known as G. intestinalis and G. duodenalis], adenovirus F 40/41, astrovirus, norovirus GI/GII, rotavirus A, sapovirus [Genogroups I, II, IV, and V])"
41	0098U	New--Proprietary Laboratory Analyses	"Respiratory pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 14 targets (adenovirus, coronavirus, human metapneumovirus, influenza A, influenza A subtype H1, influenza A subtype H3, influenza A subtype H1-2009, influenza B, parainfluenza virus, human rhinovirus/enterovirus, respiratory syncytial virus, Bordetella pertussis, Chlamydophila pneumoniae, Mycoplasma pneumoniae)"
42	0099U	New--Proprietary Laboratory Analyses	"Respiratory pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 20 targets (adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus, coronavirus OC43, human metapneumovirus, influenza A, influenza A subtype, influenza A subtype H3, influenza A subtype H1-2009, influenza, parainfluenza virus, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, human rhinovirus/enterovirus, respiratory syncytial virus, Bordetella pertussis, Chlamydophila pneumonia, Mycoplasma pneumoniae)"
43	0100U	New--Proprietary Laboratory Analyses	"Respiratory pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 20 targets (adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, human metapneumovirus, human rhinovirus/enterovirus, influenza A, including subtypes H1, H1-2009, and H3, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, respiratory syncytial virus, Bordetella parapertussis [IS1001], Bordetella pertussis [ptxP], Chlamydia pneumoniae, Mycoplasma pneumoniae)"
44	0101U	New--Proprietary Laboratory Analyses	"Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with MRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only])"
45	0102U	New--Proprietary Laboratory Analyses	"Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with MRNA analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication])"
46	0103U	New--Proprietary Laboratory Analyses	"Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with MRNA analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], EPCAM [deletion/duplication only])"
48	0104U	New--Proprietary Laboratory Analyses	"Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with MRNA analytics to resolve variants of unknown significance when indicated (32 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only])"
47	80XX0	New--Chemistry	Adalimumab
48	80XX1	New--Chemistry	Infliximab
49	80XX2	New--Chemistry	Lacosamide
50	802X0	New--Chemistry	Posaconazole
51	802XX	New--Chemistry	Vedolizumab
52	802X1	New--Chemistry	Voriconazole
53	8XX0X	New--Molecular Pathology	"Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities"
55	81406	Revise--Molecular Pathology	"Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons)"
56	81350	Revise--Molecular Pathology	"UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, drug metabolism, hereditary unconjugated hyperbilirubinemia [Gilbert syndrome]) gene analysis, common variants (eg, *28, *36, *37)      "
57	81404	Revise--Molecular Pathology	"Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)

UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, hereditary unconjugated hyperbilirubinemia [Crigler-Najjar syndrome]) full gene sequence"
58	81407	Revise--Molecular Pathology	"Molecular pathology procedure, Level 8 (eg, analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform)

APOB (apolipoprotein B) (eg, familial hypercholesterolemia type B) full gene sequence"
54	815X0	New--Molecular Pathology	"Oncology (breast), mRNA gene expression profiling by RT-PCR of 12 genes (8 content and 4 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk score"
55	815XX	New--Molecular Pathology	"Oncology (prostate), mRNAmicroarray geneexpression profiling of 22 content genes, utilizing formalin-fixed paraffin-embeddedtissue,algorithmreported as metastasis risk score"
56	8XXXX	New--Microbiology	"Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma genitalium, amplified probe technique"
57	0105U	New--Proprietary Laboratory Analyses	"Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD)"
58	0106U	New--Proprietary Laboratory Analyses	"Gastric emptying, serial collection of 7 timed breath specimens, non-radioisotope carbon-13 (13C) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of 13CO2 excretion"
59	0107U	New--Proprietary Laboratory Analyses	"Clostridium difficile toxin(s) antigen detection by immunoassay technique, stool, qualitative, multiple-step method"
60	0108U	New--Proprietary Laboratory Analyses	"Gastroenterology (Barretts esophagus), whole slidedigital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer"
61	0109U	New--Proprietary Laboratory Analyses	"Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species (A. fumigatus, A. terreus, A. niger, and A. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species"
62	0110U	New--Proprietary Laboratory Analyses	"Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected"
63	0111U	New--Molecular Pathology Proprietary Laboratory Analyses	"Oncology (colon cancer), targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis, utilizing formalin-fixed paraffin-embedded tissue"
64	0112U	New--Molecular Pathology Proprietary Laboratory Analyses	"Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene"
65	0113U	New--Proprietary Laboratory Analyses	"Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk score"
66	0114U	New--Proprietary Laboratory Analyses	"Gastroenterology (Barretts esophagus), VIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barretts esophagus"
67	0115U	New--Proprietary Laboratory Analyses	"Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected"
68	0116U	New--Proprietary Laboratory Analyses	"Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with LC-MS/MS, oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug to drug interactions for prescribed medications"
69	0117U	New--Proprietary Laboratory Analyses	"Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA), quinolinic acid, kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain "
70	0118U	New--Proprietary Laboratory Analyses	"Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA"
71	0119U	New--Proprietary Laboratory Analyses	"Cardiology, ceramides by liquid chromatographytandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events"
72	0120U	New--Proprietary Laboratory Analyses	"Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter"
73	0121U	New--Proprietary Laboratory Analyses	"Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood"
74	0122U	New--Proprietary Laboratory Analyses	"Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood"
75	0123U	New--Proprietary Laboratory Analyses	"Mechanical fragility, RBC, shear stress and spectral analysis profiling"
76	0124U	New--Proprietary Laboratory Analyses	"Fetal congenital abnormalities, biochemical assays of 3 analytes (free beta-hCG, PAPP-A, AFP), time-resolved fluorescence immunoassay, maternal dried-blood spot, algorithm reported as risk scores for fetal trisomies 13/18 and 21"
77	0125U	New--Proprietary Laboratory Analyses	"Fetal congenital abnormalities and perinatal complications, biochemical assays of 5 analytes (free beta-hCG, PAPP-A, AFP, placental growth factor, and inhibin-A), time-resolved fluorescence immunoassay, maternal serum, algorithm reported as risk scores for fetal trisomies 13/18, 21, and preeclampsia"
78	0126U	New--Proprietary Laboratory Analyses	"Fetal congenital abnormalities and perinatal complications, biochemical assays of 5 analytes (free beta-hCG, PAPP-A, AFP, placental growth factor, and inhibin-A), time-resolved fluorescence immunoassay, includes qualitative assessment of Y chromosome in cell-free fetal DNA, maternal serum and plasma, predictive algorithm reported as a risk scores for fetal trisomies 13/18, 21, and preeclampsia"
79	0127U	New--Proprietary Laboratory Analyses	"Obstetrics (preeclampsia), biochemical assays of 3 analytes (PAPP-A, AFP, and placental growth factor), time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia"
80	0128U	New--Proprietary Laboratory Analyses	"Obstetrics (preeclampsia), biochemical assays of 3 analytes (PAPP-A, AFP, and placental growth factor), time-resolved fluorescence immunoassay, includes qualitative assessment of Y chromosome in cell-free fetal DNA, maternal serum and plasma, predictive algorithm reported as a risk score for preeclampsia"
81	0129U	New--Proprietary Laboratory Analyses	"Hereditary breast cancerrelated disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis and deletion/duplication analysis panel (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, and TP53)"
82	0130U	New--Proprietary Laboratory Analyses	"Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for primary procedure)"
83	0131U	New--Proprietary Laboratory Analyses	"Hereditary breast cancerrelated disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure)"
84	0132U	New--Proprietary Laboratory Analyses	"Hereditary ovarian cancerrelated disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in addition to code for primary procedure)"
85	0133U	New--Proprietary Laboratory Analyses	"Hereditary prostate cancerrelated disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure)"
86	0134U	New--Proprietary Laboratory Analyses	"Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure)"
87	0135U	New--Proprietary Laboratory Analyses	"Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure)"
88	0136U	New--Proprietary Laboratory Analyses	"ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure)"
89	0137U	New--Proprietary Laboratory Analyses	"PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)"
90	0138U	New--Proprietary Laboratory Analyses	"BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)"
